Trials on Brain, nerves and eye13

The following clinical trials are currently offered in Germany in this group.

13 matching trials

SIOP Ependymoma II (ET-13-002)Recruiting

An international clinical program for the diagnosis and treatment of children with ependymoma (SIOP-EP-II)

Ependymomas are rare malignant cancers of the central nervous system that primarily affect children and adolescents. The goal of the SIOP-EP-II study is to improve treatment and, consequently, the chances of cure for ependymomas through improved diagnostics and optimized treatment plans. Patients under the age of 22 with a newly diagnosed WHO Grade 2 or 3 ependymoma are eligible to participate if they have not yet received treatment.

0–22 years · First line · Phase II/III

INFORM RegistryRecruiting

INFORM Registry Study on Individualized Treatment for Patients with Recurrent Malignant Disease, with a Special Focus on Children and Adolescents

Many types of cancer can now be cured using modern treatment options. Nevertheless, relapses and progressive cancer remain a major challenge. The goal of the INFORM-REGISTER study is to use molecular genetic testing methods to gather information about tumor characteristics that can be used by treating physicians to inform future treatment decisions. Patients aged 0 to 40 with previously treated, treatment-resistant, or progressive cancer who no longer have any established curative treatment options available are eligible to participate in the study.

0–40 years · Relapsed / refractory · Phase IV

IMA401-101Recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of a New Drug (Name: IMA401) in Patients with Recurrent or Uncontrolled Breast Cancer

Solid tumors are cancers that develop in organs such as the lungs, liver, or breast. When these tumors progress and no longer respond to standard therapies, novel drugs may be considered as additional treatment options. The goal of the IMA401-TCER study is to investigate the safety and tolerability of the new drug IMA401, which specifically targets certain cancer cells. Eligible participants include women and men aged 18 and older with advanced or metastatic solid tumors, including breast cancer, that no longer respond to standard therapies and exhibit a specific genetic profile (HLA-positive and MAGEA4/8).

18 years and older · Relapsed / refractory · Phase I

PYNNACLERecruiting

PYNNACLE Trial with Rezatapopt (PC14586): A New Treatment for Advanced Tumors with the TP53 Y220C Mutation

Rezatapopt is a novel, as-yet-unapproved drug that was developed specifically for the Y220C mutation in the TP53 gene. This gene controls cell growth; when a mutation occurs, the p53 protein loses its protective function, allowing cancer cells to multiply uncontrollably. Rezatapopt is intended to restore the function of the p53 protein. The PYNNACLE study is intended for patients with advanced solid tumors who have this specific genetic alteration (TP53 Y220C mutation). The goal of the study is to investigate the safety and efficacy of the investigational drug Rezatapopt. Eligible participants include women and men aged 18 and older, and, under certain conditions, adolescents between the ages of 12 and 17. The tumors must carry the TP53 Y220C mutation and must have already been treated with at least one prior cancer therapy.

12 years and older · Relapsed / refractory · Phase I/II

UKM2013_0034Recruiting

Clinical Safety Study on the Use of 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents with Brain Tumors

5-Aminolevulinic acid (5-ALA) is a substance used during surgery to highlight brain tumors so they can be safely removed. It is routinely used in adults but has not yet been approved for use in children and adolescents. The goal of the study is to collect data on the safety and efficacy of 5-ALA in children and adolescents. Children and adolescents between the ages of 3 and 17 with a brain tumor for which surgical removal is planned are eligible to participate in the study.

3–17 years · Phase II

PRIDERecruiting

Study on the Treatment of Glioblastomas: Investigation of the Combination of Radiochemotherapy and the Drug Bevacizumab (VEGF Inhibitor)

Glioblastoma is one of the most common and malignant brain tumors in adults. Despite intensive standard treatment consisting of surgery, radiation therapy, and chemotherapy, the disease usually progresses rapidly, often recurs, and has a poor prognosis. The goal of the PRIDE study is to investigate the efficacy and safety of a higher radiation dose as part of standard treatment in combination with the drug bevacizumab. Eligible participants are adult patients between the ages of 18 and 70 with newly diagnosed glioblastoma and the genetic characteristics of IDH wild-type and an unmethylated MGMT promoter.

18–70 years · First line · Phase II

SIOP-HRMBRecruiting

Comparison of Different Radiation Treatment Strategies for High-Risk Medulloblastoma in Children (Ages 3–21)

The standard treatment for high-risk medulloblastoma in children consists of a combination of surgery, radiation therapy, and chemotherapy. To further improve the chances of a cure, new treatment approaches are being investigated. The goal of the SIOP-HRMB study is to compare two new treatment approaches with the current standard of care: a modified form of radiation therapy (known as HART) or high-dose chemotherapy with thiotepa followed by standard radiation therapy. Patients between the ages of 3 and 21 who have been diagnosed with high-risk medulloblastoma, are in good general health, and have not yet received any treatment other than surgery are eligible to participate.

3–21 years · First line · Phase III

YINOTA-ORecruiting

Effectiveness of Online Yoga Therapy for Patients with Brain Tumors and Their Family Members

Malignant brain tumors place a heavy burden on patients and their families and can cause symptoms of depression and anxiety. Regular yoga sessions can be used as a supportive measure and may improve quality of life for those affected. The goal of the YINOTA-O study is to investigate the effects of an online yoga program on patients’ emotional distress, quality of life, and stress-related physiological risk factors. Women and men aged 18 and older who have a high-grade brain tumor or who are family members of such patients are eligible to participate in this study.

18 years and older · Phase II

COCOONRecruiting

Supportive Coaching for Patients with Glioblastoma and Their Families—and How It Influences Adherence to Treatment with Tumor Therapy Fields (TTFields) (COCOON Study)

As part of the treatment for glioblastoma, Tumor Therapy Fields (TTFields) can slow the progression of the tumor by generating weak alternating electric fields. The treatment is part of the standard of care, and for optimal effectiveness, the therapy device must be worn daily for many hours. The goal of the COCOON study is to investigate whether targeted coaching can help patients use TTFields therapy more regularly and for a longer period of time. The study is open to women and men aged 18 and older with a new diagnosis of glioblastoma or an IDH-mutated WHO Grade 4 astrocytoma who are scheduled to receive combined chemoradiotherapy with temozolomide and a radiation dose of 60 Gy, followed by TTFieldstherapy. Family members of these patients may also participate in the study.

18 years and older · First line

CNS-InterREST GPOHIn preparation

International Clinical Registry for Patients with Rare Embryonal or Sarcomatous Tumors of the Central Nervous System within the German Society for Pediatric Oncology and Hematology

Children and adolescents with rare embryonic or sarcomatous brain tumors currently have no standard treatments, as these conditions have only recently become diagnosable using modern methods. The goal of the CNS-InterREST GPOH study is to improve treatment options and survival rates by collecting clinical and genetic data. Children and adolescents up to age 18 who have been diagnosed with such a rare tumor are eligible to participate, provided that written consent is obtained from the child (depending on age) and/or the legal guardian.

0–18 years